{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:29:11Z","timestamp":1774870151895,"version":"3.50.1"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["FIS 11\/02167"],"award-info":[{"award-number":["FIS 11\/02167"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.pbb.2020.173012","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T12:01:40Z","timestamp":1596283300000},"page":"173012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats"],"prefix":"10.1016","volume":"197","author":[{"given":"Concepci\u00f3","family":"Marin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merc\u00e8","family":"Bonastre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireya","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim","family":"Mullol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2020.173012_bb0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesia and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Movement Disord"},{"key":"10.1016\/j.pbb.2020.173012_bb0010","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10571-007-9213-6","article-title":"Long-term L-Dopa treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats","volume":"27","author":"Borah","year":"2007","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.pbb.2020.173012_bb0015","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/brain\/114.4.1667","article-title":"Motor function of the monkey globus pallidus. 1. Neuronal discharge and parameters of movement","volume":"114","author":"Brotchie","year":"1991","journal-title":"Brain"},{"key":"10.1016\/j.pbb.2020.173012_bb0020","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/brain\/awn305","article-title":"Impact of grafted serotonin and dopamine neurons on development of L-Dopa-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration","volume":"132","author":"Carlsson","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.pbb.2020.173012_bb0025","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00702-018-1865-5","article-title":"The serotonergic system in L-Dopa-induced dyskinesia: pre-clinical evidence and clinical perspective","volume":"125","author":"Carta","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.pbb.2020.173012_bb0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fneur.2014.00078","article-title":"Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations","volume":"5","author":"Carta","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.pbb.2020.173012_bb0035","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1111\/j.1471-4159.2006.03696.x","article-title":"Role of striatal L-dopa in the production of dyskinesia in 6-hydroxydopamine lesioned rats","volume":"96","author":"Carta","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.pbb.2020.173012_bb0040","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-Dopa-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.pbb.2020.173012_bb0045","first-page":"651","article-title":"Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain","volume":"34","author":"Chernoloz","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2020.173012_bb0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1503\/jpn.110038","article-title":"Long-term administration of the dopamine D3\/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain","volume":"37","author":"Chernoloz","year":"2012","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.pbb.2020.173012_bb0055","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/mds.26144","article-title":"Serotonergic markers in Parkinson\u2019s disease and Levodopa-induced dyskinesias","volume":"30","author":"Cheshire","year":"2015","journal-title":"Movement Dis"},{"key":"10.1016\/j.pbb.2020.173012_bb0060","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/mds.1091","article-title":"Chronic L-Dopa administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl3 nigrostriatal lesions","volume":"16","author":"Datla","year":"2001","journal-title":"Movement Disord"},{"key":"10.1016\/j.pbb.2020.173012_bb0065","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pneurobio.2016.07.002","article-title":"Expanding the repertoire of L-Dopa\u2019s actions: a comprehensive review of its functional neurochemistry","volume":"151","author":"De Deurwaerd\u00e8re","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.pbb.2020.173012_bb0070","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.neuroscience.2011.11.024","article-title":"Effects of noradrenaline and serotonin depletions on the neuronal activity of globus pallidus and substantia nigra pars reticulate in experimental parkinsonism","volume":"202","author":"Delaville","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2020.173012_bb0075","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","article-title":"Primate models of movement disorders of basal ganglia origin","volume":"13","author":"DeLong","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.pbb.2020.173012_bb0080","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/BF01485901","article-title":"Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behaviour in diseases of the extrapyramidal system","volume":"38","author":"Ehringer","year":"1960","journal-title":"Klin. Wochenschr."},{"key":"10.1016\/j.pbb.2020.173012_bb0085","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/ejn.12164","article-title":"Quantitative and ultrastructural study of serotonin innervation of the globus pallidus in squirrel monkeys","volume":"37","author":"Eid","year":"2013","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pbb.2020.173012_bb0090","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/syn.20630","article-title":"The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats","volume":"63","author":"Eskow","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.pbb.2020.173012_bb0095","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/1098-2396(20010315)39:4<288::AID-SYN1011>3.0.CO;2-V","article-title":"Serotonin 5-HT (1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys","volume":"39","author":"Frechilla","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.pbb.2020.173012_bb0100","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1007\/s00429-015-1125-5","article-title":"Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys","volume":"221","author":"Gagnon","year":"2016","journal-title":"Brain Struct. Funct."},{"key":"10.1016\/j.pbb.2020.173012_bb0105","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/gt.2010.71","article-title":"BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington\u2019s disease","volume":"17","author":"Giralt","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.pbb.2020.173012_bb0110","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1017\/S1461145707008383","article-title":"Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions","volume":"11","author":"Guiard","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2020.173012_bb0115","first-page":"1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.pbb.2020.173012_bb0120","first-page":"19","article-title":"Biochemical pathophysiology of Parkinson\u2019s disease","volume":"45","author":"Hornykiewicz","year":"1987","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.pbb.2020.173012_bb0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2217\/nmt-2018-0017","article-title":"5-HT1A agonists and dyskinesia in Parkinson\u2019s disease: a pharmacological perspective","volume":"8","author":"Huot","year":"2018","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.pbb.2020.173012_bb0130","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1471-4159.2005.03625.x","article-title":"Pramipexole protects against MPTP toxicity in non-human primates","volume":"96","author":"Iravani","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.pbb.2020.173012_bb0135","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1179\/174313206X153996","article-title":"The effects of L-2-4dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models","volume":"29","author":"Jeon","year":"2007","journal-title":"Neurol. Res."},{"key":"10.1016\/j.pbb.2020.173012_bb0140","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2020.173012_bb0145","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0014-4886(03)00096-7","article-title":"Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole","volume":"183","author":"Kemmerer","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.pbb.2020.173012_bb0150","first-page":"120","article-title":"Preferential loss of serotonin markers in caudate versus putamen in Parkinson\u2019s disease","volume":"131","author":"Kish","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.pbb.2020.173012_bb0155","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bbr.2008.06.021","article-title":"Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism","volume":"194","author":"Larramendy","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2020.173012_bb0160","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1212\/WNL.0000000000001909","article-title":"Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease","volume":"85","author":"Lee","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2020.173012_bb0165","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/j.1471-4159.2008.05848.x","article-title":"Chronic intermittent L-Dopa treatment induced changes in dopamine release","volume":"108","author":"Lundblad","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.pbb.2020.173012_bb0170","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1460-9568.2009.06877.x","article-title":"Effects of early vs late initiation of levodopa treatment in hemiparkinsonian rats","volume":"30","author":"Marin","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pbb.2020.173012_bb0175","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.expneurol.2013.10.006","article-title":"Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson\u2019s disease","volume":"250","author":"Marin","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.pbb.2020.173012_bb0180","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nbd.2013.12.009","article-title":"Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats","volume":"64","author":"Marin","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2020.173012_bb0185","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuropharm.2015.06.004","article-title":"From unilateral to bilateral parkinsonism: effects of lateralization on dyskinesias and associated molecular mechanisms","volume":"97","author":"Marin","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2020.173012_bb0190","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S146114571000043X","article-title":"Locus coeruleus and dorsal raphe neuron activity and response to acute antidepressant administration in a rat model of Parkinson\u2019s disease","volume":"14","author":"Miguelez","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2020.173012_bb0195","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.neuropharm.2012.11.016","article-title":"L-DOPA modifies the antidepressant-like effects of reboxetine and fluoxetine in rats","volume":"67","author":"Miguelez","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2020.173012_bb0200","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1111\/bph.13447","article-title":"The acute and long-term L-DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6-OHDA-lesioned rats","volume":"173","author":"Miguelez","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2020.173012_bb0205","first-page":"26","article-title":"Interactions between the serotonergic and other neurotransmitter systems in the basal ganglia: role in Parkinson\u2019s disease and adverse effects of L-Dopa","volume":"14","author":"Mu\u00f1oz","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.pbb.2020.173012_bb0210","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12035-011-8230-0","article-title":"Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson\u2019s disease","volume":"45","author":"Navailles","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pbb.2020.173012_bb0215","first-page":"323686","article-title":"Imbalanced dopaminergic transmission mediated by serotonergic neurons in L-Dopa-induced dyskinesia","volume":"2012","author":"Navailles","year":"2012","journal-title":"Parkinson\u2019s Disease"},{"key":"10.1016\/j.pbb.2020.173012_bb0220","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nbd.2010.01.012","article-title":"Serotonergic neurons mediate ectopic release of dopamine induced by L-Dopa in a rat model of Parkinson\u2019s disease","volume":"38","author":"Navailles","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2020.173012_bb0225","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1021\/cn400046e","article-title":"Multisite intracerebral microdialysis to study the mechanism of L-Dopa induced dopamine and serotonin release in the parkinsonian brain","volume":"4","author":"Navailles","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.pbb.2020.173012_bb0230","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1471-4159.2011.07292.x","article-title":"Dopamine release from serotonergic nerve fibers is reduced in L-Dopa-induced dyskinesia","volume":"118","author":"Nevalainen","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.pbb.2020.173012_bb0235","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neuroscience.2013.12.029","article-title":"Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia","volume":"260","author":"Nevalainen","year":"2014","journal-title":"Neuroscience"},{"issue":"Suppl. 1","key":"10.1016\/j.pbb.2020.173012_bb0240","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jnc.13750","article-title":"Current and experimental treatments of Parkinson disease: a guide for neuroscientists","volume":"139","author":"Oertel","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.pbb.2020.173012_bb0245","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00702-017-1823-7","article-title":"The serotonergic system in Parkinson\u2019s patients with dyskinesia: evidence from imaging studies","volume":"125","author":"Pagano","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.pbb.2020.173012_bb0250","first-page":"45","article-title":"Extrastriatal dopamine and Parkinson\u2019s disease","volume":"86","author":"Parent","year":"2001","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.pbb.2020.173012_bb0255","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jchemneu.2011.04.005","article-title":"Serotonin innervation of basal ganglia in monkeys and humans","volume":"41","author":"Parent","year":"2011","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.pbb.2020.173012_bb0260","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson\u2019s disease: a randomized controlled trial. Parkinson study group","volume":"284","author":"Parkinson Study Group","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2020.173012_bb0265","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1986"},{"key":"10.1016\/j.pbb.2020.173012_bb0270","first-page":"141","article-title":"Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson\u2019s disease","volume":"21","author":"Piercey","year":"1998","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.pbb.2020.173012_bb0275","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.nbd.2010.05.028","article-title":"Staging of serotonergic dysfunction in Parkinson\u2019s disease: an in vivo 11C-DASB PET study","volume":"40","author":"Politis","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2020.173012_bb0280","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/mds.23743","article-title":"Graft-induced dyskinesias in Parkinson\u2019s disease: high striatal serotonin\/dopamine transporter","volume":"26","author":"Politis","year":"2011","journal-title":"Movement Disord."},{"key":"10.1016\/j.pbb.2020.173012_bb0285","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsable for levodopa-induced dyskinesia in Parkinson\u2019s disease patients","volume":"124","author":"Politis","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.pbb.2020.173012_bb0290","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.expneurol.2013.06.015","article-title":"Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson\u2019s disease","volume":"248","author":"Prinz","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.pbb.2020.173012_bb0295","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fnana.2010.00139","article-title":"Extrastriatal dopaminergic circuits of the basal ganglia","volume":"4","author":"Rommelfanger","year":"2010","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.pbb.2020.173012_bb0300","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1212\/WNL.0000000000002494","article-title":"Serotonin-to-dopamine transporter ratios in Parkinson disease: relevance for dyskinesias","volume":"86","author":"Roussakis","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2020.173012_bb0305","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.pbb.2020.173012_bb0310","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fnana.2017.00030","article-title":"Roles of multiple globus pallidus territories of monkeys and humans in motivation, cognition and action: an anatomical, physiological and pathophysiological review","volume":"11","author":"Saga","year":"2017","journal-title":"Front. Neuroanat."},{"issue":"Suppl. 2","key":"10.1016\/j.pbb.2020.173012_bb0315","first-page":"S47","article-title":"Drug selection and timing of initiation of treatment in early Parkinson\u2019s disease","volume":"64","author":"Schapira","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.pbb.2020.173012_bb0320","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00702-018-1871-7","article-title":"Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers","volume":"125","author":"Sgambato","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.pbb.2020.173012_bb0325","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.neurobiolaging.2014.12.037","article-title":"The role of pallidal serotonergic function in Parkinson\u2019s disease dyskinesias: a positron emission tomography study","volume":"36","author":"Smith","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.pbb.2020.173012_bb0330","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mds.22960","article-title":"Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets","volume":"25","author":"Tayarani-Binazir","year":"2010","journal-title":"Movement Disord"},{"key":"10.1016\/j.pbb.2020.173012_bb0335","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2169\/internalmedicine.52.8333","article-title":"Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson\u2019s disease","volume":"52","author":"Utsumi","year":"2013","journal-title":"Intern. Med."},{"key":"10.1016\/j.pbb.2020.173012_bb0340","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40265-016-0566-3","article-title":"Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia","volume":"76","author":"Vijayakumar","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.pbb.2020.173012_bb0345","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1474-4422(17)30004-2","article-title":"Impulse control disorders and levodopa-induced dyskinesias in Parkinson\u2019s disease: an update","volume":"16","author":"Voon","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.pbb.2020.173012_bb0350","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/j.1460-9568.2011.07621.x","article-title":"Serotonin innervation of human basal ganglia","volume":"33","author":"Wallman","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pbb.2020.173012_bb0355","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.10427","article-title":"Plasticity of the nigropallidal pathway in Parkinson\u2019s disease","volume":"53","author":"Whone","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.pbb.2020.173012_bb0360","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.nbd.2010.08.004","article-title":"Morphological changes in serotoninergic neuritis in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia","volume":"40","author":"Zeng","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2020.173012_bb0365","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/jnr.22325","article-title":"Behavioural and electrophysiological effects of 5-HT in globus pallidus of 6-hydroxydopamine lesioned rats","volume":"88","author":"Zhang","year":"2010","journal-title":"J. Neurosci. Res."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009130572030112X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009130572030112X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:38:58Z","timestamp":1758775138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009130572030112X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":73,"alternative-id":["S009130572030112X"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2020.173012","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2020.173012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173012"}}